Tela Bio Inc (TELA)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
$0.78-6.90%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-05
QuarterlyIQ Insights · TELA
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
As a result, we have taken actions to reduce our annual operating expenses by approximately $17.0 million across the organization.
Stated in 1 of 2 supplied quarters. Management reported: “At the same time, we will take decisive action to extend our cash runway and better align our cost structure with our top line.” “As a result, we have taken actions to reduce our annual operating expenses by approximately $17.0 million across the organization.” Operating income was $-9.283 million in 2026-Q2.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“At the same time, we will take decisive action to extend our cash runway and better align our cost structure with our top line.”
What is clear to me is that as we move through the second half of the year, we must improve PRS performance, accelerate our market share gains in hernia, and translate the increasing productivity of…
Stated in 2 of 2 supplied quarters. Management reported: “What is clear to me is that as we move through the second half of the year, we must improve PRS performance, accelerate our market share gains in hernia, and translate the increasing productivity of our commercial organization into sustainable top-line growth.” “and early expansion into additional European markets; · Announced the U.S. commercial launch of OviTex LTR, providing a specialized, unique, and fully resorbable, tissue-based hernia repair solution; and · Reiterated full year 2026 revenue guidance of at least 8% growth over full year 2025.” Revenue was $19.291 million in 2026-Q2.
“What is clear to me is that as we move through the second half of the year, we must improve PRS performance, accelerate our market share gains in hernia, and translate the increasing productivity of…”
“and early expansion into additional European markets; · Announced the U.S. commercial launch of OviTex LTR, providing a specialized, unique, and fully resorbable, tissue-based hernia repair solution;…”
International revenue also continued to grow, and our field organization is progressing toward the productivity levels we expected as newer territory managers gain experience."
Stated in 2 of 2 supplied quarters. Management reported: “International revenue also continued to grow, and our field organization is progressing toward the productivity levels we expected as newer territory managers gain experience."” “Recent Highlights · Announced strategic board refreshment plan to be effective at the conclusion of the 2026 Annual Meeting on June 9, 2026; · Noted the U.S. commercial organization is fully staffed at planned 2026 levels; · Delivered revenue of $19.1 million in the first quarter of 2026, representing growth of 3% over the prior year period; · Accelerated European revenue growth to 41% over the prior year period, with continued momentum in the U.K.”
“International revenue also continued to grow, and our field organization is progressing toward the productivity levels we expected as newer territory managers gain experience."”
“Recent Highlights · Announced strategic board refreshment plan to be effective at the conclusion of the 2026 Annual Meeting on June 9, 2026; · Noted the U.S. commercial organization is fully staffed…”
Liora is a fully resorbable surgical mesh device for soft tissue reinforcement that will enable TELA Bio to expand its footprint in the soft tissue reconstruction market and is the first implant to b…
Stated in 1 of 2 supplied quarters. Management reported: “On April 1st, we initiated the full U.S. commercial launch of OviTex LTR, one of the only fully resorbable, tissue-based hernia repair solutions on the market, which further broadens the OviTex portfolio to address the full spectrum of surgeon and patient needs.” “Liora is a fully resorbable surgical mesh device for soft tissue reinforcement that will enable TELA Bio to expand its footprint in the soft tissue reconstruction market and is the first implant to be fully developed in the Company’s ISO 8 certified cleanroom in Malvern, PA.”
“On April 1st, we initiated the full U.S. commercial launch of OviTex LTR, one of the only fully resorbable, tissue-based hernia repair solutions on the market, which further broadens the OviTex portf…”
Keep the U.S. commercial sales team fully staffed as planned for 2026 to support sales execution and growth targets.
Over the trailing year it converted 1.10x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
16 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.